Research Article
Risk Factors for Chemotherapy-Induced Peripheral Neuropathy Caused by Nanoparticle Albumin-Bound Paclitaxel in Advanced Breast Cancer
Table 3
A univariate analysis performed on the CIPN group and non-neurotoxicity group (
).
| | Group | CIPN patients (53) | Non-neurotoxicity patients (37) | value |
| | Age | | | 0.143 | | <55 | 34 (64.1) | 18 (48.6) | | | ≥55 | 19 (35.8) | 19 (51.3) | | | BMI | | | 0.188 | | <24.9 | 30 (56.6) | 26 (70.2) | | | ≥25 | 23 (43.3) | 11 (29.7) | | | BSA | | | 0.106 | | <1.6 | 5 (9.4) | 8 (21.6) | | | ≥1.6 | 48 (90.5) | 29 (78.3) | | | Pathological type | | | 0.127 | | IDC | 37 (69.8) | 20 (54) | | | Others | 16 (30.1) | 17 (45.9) | | | Clonal subpopulations | | | 0.09 | | HER2+ | 7 (13.2) | 3 (8.1) | | | TNBC | 22 (41.5) | 12 (32.4) | | | Luminal A | 5 (9.4) | 1 (2.7) | | | Luminal B (HER2-) | 14 (26.4) | 20 (54) | | | Luminal B (HER2+) | 5 (9.4) | 1 (2.7) | | | ECOG score | | | 0.299 | | 0~1 | 43 (81.3) | 33 (89.1) | | | 2 | 10 (18.8) | 4 (10.8) | | | Usage and dosage | | | 0.821 | | 200 mg QW | 37 (68.5) | 25 (67.5) | | | 400 mg Q3W | 16 (29.6) | 12 (32.4) | | | Chemotherapy cycles | | | 0.037 | | ≤4 cycles | 17 (32) | 20 (54) | | | >4 cycles | 36 (68) | 17 (45.9) | | | Chemotherapy regimens | | | 0.336 | | Single | 19 (35.8) | 17 (45.9) | | | Combination | 34 (64.1) | 20 (54) | | | First-line treatment of nab-paclitaxel | | | 0.042 | | Yes | 20 (37.7) | 22 (59.5) | | | No | 33 (62.3) | 15 (40.5) | | | Metastatic lesions | | | 0.641 | | 1~2 | 27 (50.9) | 17 (45.9) | | | ≥3 | 26 (49) | 20 (54) | | | Previous diseases | | | 0.431 | | Yes | 23 (43.4) | 13 (35.1) | | | No | 30 (56.6) | 24 (64.9) | |
|
|
BMI: body mass index; BSA: body surface area; ECOG: Eastern Cooperative Oncology Group.
|
